Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Trade War‘s Next Frontier? China Genetic Material Regs Could Set Back Biopharma Research

Executive Summary

A new rule regulating the collecting, storing and transporting of genetic samples and materials in China sets new limits on international companies looking to conduct work with biologic and gene therapies in potentially the most promising market for these emerging technologies.

You may also be interested in...



Gene And Cell Therapies In Asia: Can China Deliver Despite Murky Regulations?

The first country ever to approve a gene therapy, China has subsequently lagged in the area due to a lack of clear regulatory pathways and insufficient financial incentives. Now a new crop of developers are aiming to revitalize ambitions and make the country a major power for promising novel treatments for rare neurodegenerative conditions, retinal dystrophy, HIV and cancer.

Chinese Scientist Behind Gene Edited Babies Gets 3 Year Jail Term

Scientific experiment now a criminal charge and the scientist He Jiankui is sentenced to three years in prison and also levied a fine.Two collaborators face similar fate.

Gene And Cell Therapies In Asia: Can China Deliver Despite Murky Regulations?

The first country ever to approve a gene therapy, China has been lagging in the area since due to a lack of clear regulatory pathways and insufficient financial incentives. Now a new crop of developers are aiming to revitalize ambitions and make the country a major power for promising novel treatments for rare neurodegenerative conditions, retinal dystrophy, HIV and cancer.

Topics

Related Companies

UsernamePublicRestriction

Register

PS125446

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel